Dilated Cardiomyopathy

  • Shinji Katsuragi
  • Tomoaki Ikeda


Women with preexisting cardiomyopathy, such as dilated cardiomyopathy, who are followed closely during pregnancy often tolerate pregnancy and delivery. Many symptoms of a normal pregnancy can mimic heart failure in the antepartum period, and repeated maternal echocardiographic imaging is necessary during pregnancy. Risk factors for adverse outcomes include functional status at baseline and severity of systolic dysfunction. Beta-blockers are generally safe during pregnancy, but some reports suggest that they can cause intrauterine growth restriction. Cardiac complications such as worsening heart failure accompanied by worsening left ventricular ejection fraction (LVEF), arrhythmias, and cerebrovascular accidents occur most commonly in late pregnancy, as well as in the first 16 months postpartum. The level of brain natriuretic peptide (BNP) can be used to risk stratify women for adverse events. Pregnant women with dilated cardiomyopathy should be followed closely by a multidisciplinary team comprised of nurses, obstetricians, neonatologists, cardiologists, anesthesiologists, and cardiac surgeons. The team should ideally discuss a delivery plan prior to commencement of labor, with identification of the type of labor, anesthesia, and need for invasive hemodynamic monitoring.


Pregnancy Dilated cardiomyopathy Ejection fraction NYHA class 


  1. 1.
    Bernstein PS, Magriples U (2001) Cardiomyopathy in pregnancy: a retrospective study. Am J Perinatol 18:163–168CrossRefGoogle Scholar
  2. 2.
    Burkett EL, Hershberger RE (2005) Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45:969–981CrossRefGoogle Scholar
  3. 3.
    Sivasankaran S, Sharland GK, Simpson JM (2005) Dilated cardiomyopathy presenting during fetal life. Cardiol Young 15:409–416CrossRefGoogle Scholar
  4. 4.
    Judge DP (2009) Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 302:2471–2476CrossRefGoogle Scholar
  5. 5.
    Dellefave L, McNally EM (2010) The genetics of dilated cardiomyopathy. Curr Opin Cardiol 25:198–204CrossRefGoogle Scholar
  6. 6.
    Hershberger RE, Morales A, Siegfried JD (2010) Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 12:655–667CrossRefGoogle Scholar
  7. 7.
    Hershberger RE, Siegfried JD (2011) State of the art review. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57:1641–1649CrossRefGoogle Scholar
  8. 8.
    Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239CrossRefGoogle Scholar
  9. 9.
    Roos-Hesselink J, Ruys T, Stein J, Thilén U, Webb G, Niwa K et al (2013) Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J 34:657–665CrossRefGoogle Scholar
  10. 10.
    Vanita S, Neelam A, Arun K, Seema C, Pooja S, Rajesh V (2013) Pregnancy with dilated and peripartum cardiomyopathy: maternal and fetal outcome. Arch Gynecol Obstet 287:195–199CrossRefGoogle Scholar
  11. 11.
    Katsuragi S, Omoto A, Kamiya C, Ueda K, Sasaki Y, Yamanaka K et al (2012) Risk factors for maternal outcome in pregnancy complicated with dilated cardiomyopathy. J Perinatol 32:170–175CrossRefGoogle Scholar
  12. 12.
    Grewal J, Siu S, Ross H, Mason J, Balint O, Sermer M et al (2010) Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 55:45–52CrossRefGoogle Scholar
  13. 13.
    European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L, ESC Committee for Practice Guidelines (2011) ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32:3147–3197CrossRefGoogle Scholar
  14. 14.
    Thorne S, MacGregor A, Nelson-Piercy C (2006) Risks for contraception and pregnancy in heart disease. Heart 92:1520–1525CrossRefGoogle Scholar
  15. 15.
    Gevaert S, Paum M, Tromp F, Ascoop A, Roelens K et al (2014) Treatment of pre-existing cardiomyopathy during pregnancy. Acta Cardiol 69:193–196CrossRefGoogle Scholar
  16. 16.
    Cooper WO, Heenandez-Diaz S, Arbogast PG, Dudly JA, Dyer S, Gideon PS et al (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443–2451CrossRefGoogle Scholar
  17. 17.
    Messina M, Biffignandi P, Ghigo E, Jeanter MG, Molinatti GM (1979) Possible contraindication of spironolactone during pregnancy. J Endocrinol Investig 2:222CrossRefGoogle Scholar
  18. 18.
    Widerhorn J, Rubin JN, Frishman WH, Elkayam U (1987) Cardiovascular drugs in pregnancy. Cardiol Clin 5:651–674CrossRefGoogle Scholar
  19. 19.
    Tanaka K, Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M et al (2016) Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J 80:2221–2226CrossRefGoogle Scholar
  20. 20.
    Meidahl PK, Jimenez SE, Andersen JT, Petersen M, Brodbaek K, Kober L et al (2012) β-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2:e001185CrossRefGoogle Scholar
  21. 21.
    Kathleen S, Elaine S, Travis B (2011) Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol 58:337–350CrossRefGoogle Scholar
  22. 22.
    Hameed AB, Chan K, Ghamsary M, Elkayam U (2009) Longitudinal changes in the B-type natriuretic peptide levels in normal pregnancy and postpartum. Clin Cardiol 32:E60–E62CrossRefGoogle Scholar
  23. 23.
    Resnik JL, Hong C, Resnik R et al (2005) Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 193:450–454CrossRefGoogle Scholar
  24. 24.
    Folk JJ, Lipari CW, Nosovitch JT, Silverman RK, Carlson RJ, Navone AJ (2005) Evaluating ventricular function with B-type natriuretic peptide in obstetric patients. J Reprod Med 50:147–154PubMedGoogle Scholar
  25. 25.
    Borghi C, Esposti DD, Immordino V et al (2000) Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 183:140–147CrossRefGoogle Scholar
  26. 26.
    Rafik Hamad R, Larsson A, Pernow J, Bremme K, Eriksson MJ (2009) Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens 27:2257–2264CrossRefGoogle Scholar
  27. 27.
    Tanous D, Siu SC, Mason J et al (2010) B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 56:1247–1253CrossRefGoogle Scholar
  28. 28.
    Howlett JG, McKelvie RS, Costigan J et al (2010) The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 26:185–202CrossRefGoogle Scholar
  29. 29.
    Secher NJ, Thayssen P, Arnsbo P, Olsen J (1982) Effect of prostaglandin E2 and F2alpha on the systemic and pulmonary circulation in pregnant anesthetized women. Acta Obstet Gynecol Scand 61:213–218CrossRefGoogle Scholar
  30. 30.
    Siu SC, Sermer M, Harrison DA et al (1997) Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 96:2789–2794CrossRefGoogle Scholar
  31. 31.
    Geva T, Mauer MB, Striker L, Kirshon B, Pivarnik JM (1997) Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Am Heart J 133:53–59CrossRefGoogle Scholar
  32. 32.
    Pryn A, Bryden F, Reeve W, Young S, Patrick A, McGrady EM (2007) Cardiomyopathy in pregnancy and caesarean section: four case reports. Int J Obstet Anesth 16:68–73CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2019

Authors and Affiliations

  • Shinji Katsuragi
    • 1
  • Tomoaki Ikeda
    • 2
  1. 1.Department of Obstetrics and GynecologySakakibara Heart InstituteFuchuJapan
  2. 2.Department of Obstetrics and GynecologyMie University Graduate School of MedicineTsuJapan

Personalised recommendations